@article{oai:nagoya.repo.nii.ac.jp:00024736,
 author = {Shibata, Masahiro and Kanda, Mitsuro and Shimizu, Dai and Tanaka, Haruyoshi and Umeda, Shinichi and Hayashi, Masamichi and Inaishi, Takahiro and Miyajima, Noriyuki and Adachi, Yayoi and Takano, Yuko and Nakanishi, Kenichi and Takeuchi, Dai and Noda, Sumiyo and Kodera, Yasuhiro and Kikumori, Toyone},
 issue = {6},
 journal = {Oncology Letters},
 month = {Jun},
 note = {Breast cancer (BC) is the most common malignancy among women. Identifying novel biomarkers to predict prognosis accurately is important in managing this disease. The regulatory factor X1 (RFX1) gene is a member of the regulatory factor X gene family. Its protein reportedly downregulates the proto‑oncogene c‑myc, but its role in BC has been unclear. In this study, expression and methylation status of RFX1 were determined in BC cell lines. We then evaluated RFX1 mRNA expression levels with regard to clinicopathological factors including postoperative prognosis in 167 patients with BC. Expression of RFX1 was heterogeneous among cell lines, and we found no DNA methylation at the RFX1 promoter region. Patients were categorized into groups with high or low RFX1 expression, based on ratio of RFX1 mRNA expression in BC and adjacent non‑cancerous tissues. The high RFX1 group was significantly associated with low T factor (P=0.028), earlier disease stage (P=0.015), positive expression of estrogen receptor (P=0.005) and progesterone receptor (P=0.011), negative expression of human epidermal growth factor receptor 2 (P=0.001). The high RFX1 group experienced more favorable disease‑free survival (P=0.007) and overall survival (P=0.013). In multivariate analysis, RFX1 expression was an independent prognostic factor for disease‑free survival. Our findings indicate that RFX1 may serve as a prognostic marker for BC.},
 pages = {4334--4340},
 title = {Expression of regulatory factor X1 can predict the prognosis of breast cancer},
 volume = {13},
 year = {2017}
}